Orion Oyj B
FIEUROrion Oyj B (HE:ORNBV) — Drug Manufacturers - General. Número de bolsas en las que cotizan las acciones de la empresa: 3. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la Empresa
- Sitio Web
- orionpharma.com
- Relaciones con los Inversores
- orionpharma.com/investors/investor-relations/
- Sector
- Healthcare · Drug Manufacturers - General
- Sede Central
- Espo, Finland
- Gestión
- Liisa Hurme
- Últimos Informes
- Empleados
- 4 000
- Cotiza Desde
- 07.10.2004 (HE:ORNBV)
- Acciones en Circulación
- 108.99 M
- Capital Flotante
- 123.49 M
- Capitalización Bursátil
- 11.42 mil M EUR
- Insiders
- 2.63%
- Inversores Institucionales
- 45.48%
- P/E
- 23.9
- P/B
- 11.0
- Ratio de Reparto
- 41.3%
- FCF
- 380 M EUR
- Pagos / FCF
- 64%
- Deuda
- 133 M EUR0.3 a. de FCF
- Racha de Dividendos
- 21 a.
- Beneficios, FCF y dividendos pagados — para los 12 meses hasta 30.06.2026 (el último informe de la compañía).
Descripción
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
Bolsas y Tickers
| Bolsa | Ticker | Moneda | Precio | Tipo |
|---|---|---|---|---|
| acciones ordinarias | ||||
| HE Nasdaq Helsinki | ORNBV principal | EUR | 99.5 +1.12% | acciones ordinarias |
| LSE London Stock Exchange | 0M2O IOB | EUR | 45.86 +0.00% | acciones ordinarias |
| US USA Stocks | ORINF OTC | USD | 92.05 +0.00% | acciones ordinarias |
| certificado de depósito | ||||
| US USA Stocks | ORINY | USD | 56.26 +4.19% | certificado de depósito |
Dividendos
Orion Oyj B (ORNBV) paga dividendos dos veces al año. Por año (12 meses hasta e incluyendo el último pago anunciado): 1.8 EUR por acción (pagos: 2). Eso representa aproximadamente el 1.81% del precio actual de la acción. Según el historial de pagos, se espera la próxima fecha ex-dividendo alrededor de 19.04.2027. Historial de dividendos ininterrumpido: 21 años.
Acciones Ordinarias
| Fecha Ex | Pago | Importe | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-10-19 | — | 0.9000 EUR | 1.0/2.1 % | semestral | HE:ORNBV |
| 2026-03-25 | 2026-04-02 | 0.9000 EUR | 1.3/2.6 % | semestral | HE:ORNBV |
| 2025-10-15 | 2025-10-23 | 0.8200 EUR | 1.2/2.4 % | semestral | HE:ORNBV |
| 2025-04-04 | 2025-04-14 | 0.8200 EUR | 1.5/2.9 % | semestral | HE:ORNBV |
| 2024-10-15 | 2024-10-23 | 0.8100 EUR | 1.7/3.4 % | semestral | HE:ORNBV |
| 2024-03-21 | 2024-04-03 | 0.8100 EUR | 2.3/2.3 % | anual | HE:ORNBV |
| 2023-03-23 | — | 1.6000 EUR | 3.7/3.7 % | anual | HE:ORNBV |
| 2022-03-24 | — | 1.5000 EUR | 3.5/3.5 % | anual | HE:ORNBV |
Recibos de Depósito
| Fecha Ex | Pago | Importe | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-10-20 | 2026-11-16 | 0.50688 USD | 0.9/1.8 % | regular | US:ORINY |
| 2026-03-26 | 2026-04-17 | 0.517769 USD | 0.9/2.6 % | regular | US:ORINY |
| 2025-10-16 | 2025-11-07 | 0.474903 USD | 0.8/1.7 % | regular | US:ORINY |
| 2025-04-07 | 2025-04-29 | 0.463833 USD | 0.8/1.6 % | regular | US:ORINY |
| 2024-10-16 | 2024-11-07 | 0.435739 USD | 0.8/≈1.6 % | regular | US:ORINY |
| 2024-03-21 | 2024-04-18 | 0.437521 USD | 0.8/≈0.8 % | regular | US:ORINY |
Noticias de Esta Semana
Comunicados de prensa desde la página web para inversores de la empresa, actualizados diariamente. Los enlaces conducen a la página web de la empresa. Los titulares están en el idioma original, como en la página web de la empresa.
Principales Accionistas
| Titular | Participación | Acciones | Fecha del Informe |
|---|---|---|---|
| BlackRock, Inc. | ≈6.43% | 7.07 M | 2025-04-24 |
| VANGUARD STAR FUNDS-Vang… | 1.42% | 1.56 M | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.95% | 1.04 M | 2026-06-30 |
| iShares Trust-iShares Co… | 0.75% | 825 344 | 2026-08-31 |
| DFA INVESTMENT TRUST CO-… | 0.55% | 600 779 | 2026-07-31 |
| DFA INVESTMENT DIMENSION… | 0.45% | 497 917 | 2026-07-31 |
| Fidelity Concord Street… | 0.39% | 426 245 | 2026-07-31 |
| iShares Trust-iShares MS… | 0.35% | 379 664 | 2026-08-31 |
| SPDR-EUROPE-SSgA SPDR ET… | 0.34% | 374 245 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.23% | 254 097 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.23% | 253 858 | 2026-07-31 |
| Pacer Advisors, Inc. | 0% | 485 | 2026-06-30 |
